Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „selpercatinib“
Suchtreffer
Begriffe & Kennungen
Retsevmo · 4.5 · Selpercatinib is an in vitro inhibitor of P-gp and BCRP. In vivo, selpercatinib increased Cmax and AUC of dabi
Eintrag öffnenRetsevmo · 4.5 · Selpercatinib is an in vitro inhibitor of P-gp and BCRP. In vivo, selpercatinib increased Cmax and AUC of dabi
Eintrag öffnenRetsevmo · 4.5 · Selpercatinib metabolism is through CYP3A4. Therefore, medicinal products that can influence CYP3A4 enzyme act
Eintrag öffnenRetsevmo · 4.5 · Selpercatinib metabolism is through CYP3A4. Therefore, medicinal products that can influence CYP3A4 enzyme act
Eintrag öffnenRetsevmo · 4.5 · Sensitive CYP2C8 substrates Selpercatinib increased the Cmax and AUC of repaglinide (a substrate of CYP2C8) by
Eintrag öffnenRetsevmo · 4.5 · Sensitive CYP2C8 substrates Selpercatinib increased the Cmax and AUC of repaglinide (a substrate of CYP2C8) by
Eintrag öffnenRetsevmo · 4.5 · Sensitive CYP3A4 substrates Selpercatinib increased Cmax and AUC of midazolam (a CYP3A4 substrate) by approxim
Eintrag öffnenRetsevmo · 4.5 · Sensitive CYP3A4 substrates Selpercatinib increased Cmax and AUC of midazolam (a CYP3A4 substrate) by approxim
Eintrag öffnenRetsevmo · 4.8 · 11 Table 5 Adverse drug reactions in patients receiving selpercatinib (N=1188)
Eintrag öffnenRetsevmo · 4.8 · Description of selected adverse reactions in patients receiving selpercatinib
Eintrag öffnenRetsevmo · 4.8 · Description of selected adverse reactions in patients receiving selpercatinib
Eintrag öffnenRetsevmo · 4.8 · Elderly In patients receiving selpercatinib, 24.7% were ≥65-74 years of age, 8.6% were 75-84 years of age, and
Eintrag öffnenRetsevmo · 4.8 · Elderly In patients receiving selpercatinib, 24.7% were ≥65-74 years of age, 8.6% were 75-84 years of age, and
Eintrag öffnenRetsevmo · 4.8 · Haemorrhages Grade ≥3 haemorrhagic events occurred in 2.5% of patients treated with selpercatinib across studi
Eintrag öffnenRetsevmo · 4.8 · Haemorrhages Grade ≥3 haemorrhagic events occurred in 2.5% of patients treated with selpercatinib across studi
Eintrag öffnenRetsevmo · 4.8 · Median time on treatment with selpercatinib was 30.09 months (Study LIBRETTO-001), 16.7 months (Study LIBRETTO
Eintrag öffnenRetsevmo · 4.8 · Median time on treatment with selpercatinib was 30.09 months (Study LIBRETTO-001), 16.7 months (Study LIBRETTO
Eintrag öffnenRetsevmo · 4.8 · Median time on treatment with selpercatinib was 30.26 months.
Eintrag öffnenRetsevmo · 4.8 · Median time on treatment with selpercatinib was 30.26 months.
Eintrag öffnenRetsevmo · 4.8 · Table 5 Adverse drug reactions in patients receiving selpercatinib (N=1188)
Eintrag öffnen